The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Identification and validation of an assay predictive of response and prognosis following anthracycline-based chemotherapy for early breast cancer.
Jude M. Mulligan
Employment or Leadership Position - Almac Diagnostics
Laura A. Hill
Employment or Leadership Position - Almac Diagnostics
Steve Deharo
Employment or Leadership Position - Almac Diagnostics
Katherine E. Keating
Employment or Leadership Position - Almac Diagnostics
Olaide Raji
Employment or Leadership Position - Almac Diagnostics
Fionnuala A. McDyer
Employment or Leadership Position - Almac Diagnostics
Jacqueline James
No relevant relationships to disclose
Gareth Irwin
No relevant relationships to disclose
David Boyle
No relevant relationships to disclose
Jennifer E. Quinn
No relevant relationships to disclose
Paul B. Mullan
No relevant relationships to disclose
Colin R. James
No relevant relationships to disclose
Manuel Salto-Tellez
Consultant or Advisory Role - Almac Diagnostics
Timothy S. Davison
Employment or Leadership Position - Almac Diagnostics
Patrick Johnston
Employment or Leadership Position - Almac Diagnostics
Fergus J. Couch
No relevant relationships to disclose
D. Paul Harkin
Employment or Leadership Position - Almac Diagnostics
Richard D. Kennedy
Employment or Leadership Position - Almac Diagnostics
Research Funding - Almac Diagnostics